- Report
- February 2025
- 200 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Report
- February 2025
- 185 Pages
Global
From €4279EUR$4,500USD£3,598GBP
- Report
- January 2025
- 183 Pages
Global
From €4279EUR$4,500USD£3,598GBP
- Report
- February 2025
- 200 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Report
- September 2024
- 175 Pages
Global
From €4754EUR$5,000USD£3,998GBP
- Report
- May 2024
- 135 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- May 2024
- 135 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
€1426EUR$1,500USD£1,199GBP
- Report
- April 2023
- 175 Pages
Global
From €5609EUR$5,899USD£4,716GBP
- Report
- March 2025
- 200 Pages
India
From €2368EUR$2,490USD£1,991GBP
From €2472EUR$2,600USD£2,079GBP
- Report
- April 2023
- 120 Pages
Global
From €4516EUR$4,750USD£3,798GBP
- Report
- April 2023
- 89 Pages
Global
From €3500EUR$3,943USD£3,046GBP

Levofloxacin is a broad-spectrum antibiotic used to treat a variety of bacterial infections. It belongs to the class of antibiotics known as fluoroquinolones, which are used to treat a wide range of bacterial infections, including respiratory, urinary tract, and skin infections. Levofloxacin is effective against both Gram-positive and Gram-negative bacteria, making it a useful tool in the treatment of many bacterial infections. It is also used to treat certain types of pneumonia, as well as some sexually transmitted diseases.
Levofloxacin is available in both oral and intravenous forms, and is generally well tolerated with few side effects. It is often prescribed as a first-line treatment for bacterial infections, as it is generally more effective than other antibiotics.
The market for Levofloxacin is highly competitive, with many companies offering the drug in various forms. Some of the major players in the market include Pfizer, Merck, Johnson & Johnson, Bayer, and Sanofi. Show Less Read more